Phase 1, single-dose escalating study of marzeptacog alfa (activated), a recombinant factor VIIa variant, in patients with severe hemophilia-Reference-Cited by-同舟云学术

Phase 1, single-dose escalating study of marzeptacog alfa (activated), a recombinant factor VIIa variant, in patients with severe hemophilia

Published:2018-08-27 Issue:10 Volume:16 Page:1984-1993
ISSN:1538-7933
Container-title:Journal of Thrombosis and Haemostasis
language:en
Short-container-title:J Thromb Haemost

Author:

Gruppo R. A.¹^ORCID,Malan D.²,Kapocsi J.³,Nemes L.⁴,Hay C. R. M.⁵,Boggio L.⁶,Chowdary P.⁷,Tagariello G.⁸,von Drygalski A.⁹^ORCID,Hua F.¹⁰,Scaramozza M.¹¹,Arkin S.¹²,

Affiliation:

1. Comprehensive Hemophilia and Thrombosis Center; Cincinnati Children's Hospital Medical Center; Cincinnati OH USA

2. Phoenix Pharma Pty Ltd; Mount Croix, Port Elizabeth South Africa

3. Semmelweis University 1st Department of Medicine; Budapest Hungary

4. National Hemophilia Center and Hemostasis Department; Medical Center of the Hungarian Defense Forces; Budapest Hungary

5. University Department of Haematology; Manchester Royal Infirmary; Manchester UK

6. Hemophilia and Thrombophilia Center; Rush University Medical Center; Chicago IL USA

7. KD Haemophilia and Thrombosis Centre; Royal Free Hospital; London UK

8. Department of Medicine; Hemophilia Center; Castelfranco Veneto Hospital; Castelfranco Italy

9. University of California San Diego; San Diego CA USA

10. Applied BioMath; Concord MA USA

11. Early Clinical Development; Pfizer Worldwide R&D; Pfizer Inc.; Cambridge MA USA

12. Rare Disease Research Unit; Pfizer Inc.; Cambridge MA USA

Funder

Pfizer

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jth.14247/fullpdf

Reference34 articles.

1. Modern hemophilia care;Berntorp;Lancet,2012

2. The hemophilias - from royal genes to gene therapy;Mannucci;N Engl J Med,2001

3. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia;Manco-Johnson;N Engl J Med,2007

4. Effects of secondary prophylaxis started in adolescent and adult hemophiliacs;Tagliaferri;Hemophilia,2008

5. Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in hemophilia B subjects;Valentino;Hemophilia,2014

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Model‐informed pediatric dose selection of marzeptacog alfa (activated): An exposure matching strategy;CPT: Pharmacometrics & Systems Pharmacology;2023-05-02

2. Congenital Factor VII Deficiency, Diagnosis, and Management;Congenital Bleeding Disorders;2023

3. Is there any place for replacement therapy of hemophilia A in children in present and future?;Russian Journal of Pediatric Hematology and Oncology;2022-11-09

4. Early stage clinical trials for the treatment of hemophilia A;Expert Opinion on Investigational Drugs;2022-11-02

5. Phase III dose selection of marzeptacog alfa (activated) informed by population pharmacokinetic modeling: A novel hemostatic drug;CPT: Pharmacometrics & Systems Pharmacology;2022-10-18